Study flags need to monitor frailty risks with GLP-1 drugs for older adults

July 15, 2026 12:05 PM

Study flags need to monitor frailty risks with GLP-1 drugs for older adults

Potential signs of frailty in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound ​may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns about how best to monitor seniors as U.S. Medicare expands access to ‌GLP-1 therapies. In general, frailty-associated conditions such as malnutrition, dehydration and loss of muscle mass and strength developed only rarely and the results should not discourage appropriate use of Zepbound, known...

Lilly says weight loss drug cut heart failure risk by 38% in trial

August 1, 2024 5:23 PM

Lilly says weight loss drug cut heart failure risk by 38% in trial

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits. The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo. The trial enrolle...